Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

July 08, 2025

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for diabetes treatment.

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 07, 2025

Australian Patients With IBD Switched to Biosimilar Infliximab Maintain Long-Term Persistence

July 05, 2025

The Top 5 Biosimilar Articles for the Week of June 30

July 04, 2025

Biosimilar SB12 Matches Eculizumab in PNH Treatment Across Diverse Patient Groups

July 03, 2025

The Hatch-Waxman Act Turns 40: The Law That Made Biosimilars Possible

February 8th 2024

By Skylar Jeremias

Article

To mark the 40th anniversary of the Hatch-Waxman Act, the Association for Accessible Medicines published a white paper outlining the benefits and challenges associated with the landmark policy as well as solutions to ensure a stable pharmaceutical industry for the future.

Vizient Report Emphasizes Biosimilar Successes, Impact of Inflation on Drug Spend

February 7th 2024

By Skylar Jeremias

Article

Vizient’s most recent Pharmacy Market Outlook report showcased the success of biosimilars while also emphasizing the impact of inflation on different drug classes, particularly in oncology and immunology.

Biosimilar Etanercept Similar to Enbrel in Persistence of Treatment, Cost Savings for Patients With RA

February 6th 2024

By Cameron Santoro

Article

Etanercept biosimilar SB4 is just as effective as the originator drug (Enbrel) in treating Australian patients with rheumatoid arthritis (RA), leading to significant cost savings.

BioRationality: Bringing the FDA and the USP Together to Revolutionize Biosimilars

February 5th 2024

By Sarfaraz K. Niazi, PhD

Article

In his latest column, Sarfaraz K. Niazi, PhD, highlights challenges in biosimilar development, emphasizing the crucial role of US Pharmacopeia (USP) and advocating for collaboration and standardized guidelines to expedite cost-effective development without compromising safety or efficacy.

Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition

February 4th 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.

Patient-Reported Experiences on Adalimumab Biosimilar SB5 and Correlation With Treatment Persistence

February 3rd 2024

By Deana Ferreri, PhD

Article

The PERFUSE study in France on biosimilar adalimumab SB5 for inflammatory bowel disease reveals high satisfaction overall, but significant variations in training and survey response rates across sites suggest a potential lack of support during treatment switches.

The Top 5 Biosimilar Articles for the Week of January 29

February 2nd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of January 29, 2024.

Biosimilars Gastroenterology Roundup: January 2024

February 1st 2024

By Skylar Jeremias

Article

In addition to the several reports that have come out quantifying how the gastroenterology biosimilar market is progressing, January marks the 1-year anniversary of adalimumab biosimilar competition in the US.

SB15 Effective, Safe in Treating nAMD Before, After Switching

February 1st 2024

By Cameron Santoro

Article

A study found SB15, an aflibercept biosimilar, is just as effective as its reference drug Eylea, the current standard treatment for neovascular age-related macular degeneration (nAMD), a condition that causes vision loss.

Happy Birthday Adalimumab Biosimilars: Reflecting on the First Year of US Competition

January 31st 2024

By Skylar Jeremias

Article

The Center for Biosimilars® looks back at the first year of adalimumab biosimilars on the US market, including every product launch and approval as well as market trends and pricing strategies.